Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe
The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.
bioRxiv · Jan 12, 2022Immunology
N. Suryadevara, S. Shrihari, P. Gilchuk, L. VanBlargan, E. Binshtein, S. Zost, R. Nargi, R. Sutton, E. S. Winkler, E. C. Chen, M. E. Fouch, E. Davidson, B. Doranz, R. H. Carnahan, L. Thackray, , J. E. Crowe
The paper identifies two NTD-specific human mAbs with neutralizing activity against SARS-CoV-2 and shows they require Fc effector functions for optimal protection.
bioRxiv · Jan 19, 2021Immunology
C. D. Murin, P. Gilchuk, P. Ilinykh, K. Huang, N. Kuzmina, X. Shen, J. F. Brunh, A. L. Brunh, E. Davidson, B. Doranz, L. E. Williamson, J. Copps, T. Alkutkar, A. I. Flyak, A. Bukreyev, , A. B. Ward
The paper presents cryo-EM structures of glycan cap antibodies that neutralize ebolavirus by targeting a conserved MLD-anchor site, revealing common features among broadly neutralizing antibodies.
bioRxiv · Oct 14, 2020Immunology
T. Kotaki, T. Kurosu, A. Grinyo, E. Davidson, S. Churrotin, T. Okabayashi, O. Puiprom, K. C. Mulyatno, T. H. Sucipto, B. Doranz, K.-i. Ono, S. Soegijanto, M. Kameoka
This study identifies an affinity-matured human monoclonal antibody, 3G9, targeting the fusion loop epitope of dengue virus that shows strong neutralization and reduced antibody-dependent enhancement in vivo.
bioRxiv · Oct 3, 2020Microbiology
P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan
This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.
bioRxiv · May 12, 2020Immunology